Estrogen Receptor mutations in breast cancer - New focus on an old target

Clinical Cancer Research

Volumn 20, Issue 7, 2014, Pages 1724-1726

  Segal, Corrinne V ^a,b   Dowsett, Mitch ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; TAMOXIFEN;

ARTICLE; CANCER HORMONE THERAPY; DRUG EFFICACY; DRUG TARGETING; ESR1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE; GENE MUTATION; HUMAN; MUTANT; MUTATION RATE; PRIMARY TUMOR; PRIORITY JOURNAL; BREAST TUMOR; GENETICS; MUTATION; NEOPLASM;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MUTATION; NEOPLASMS, HORMONE-DEPENDENT;

EID: 84898756681     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0067     Document Type: Article

References (12)

1. Jeselsohn R Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM. Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer Clin Cancer Res 2014;20:1757-67.
2. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s-8s. (Pubitemid 40111111)
3. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:1052-6. (Pubitemid 46638801)
4. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58. (Pubitemid 40065543)
5. Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, et al. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in oestrogen receptor-positive breast cancer. Ann Oncol 2014;25:605-10.
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
7. Karnik PS, Kulkarni S, Liu XP, Budd GT, Bukowski RM. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res 1994;54:349-53. (Pubitemid 24053165)
8. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
9. Robinson DR, WuYM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013;45:1446-51.
10. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, et al. D538G mutation in estrogen receptoralpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013;73:6856-64.
11. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013;4:1116-30.
12. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997;57:1244-9. (Pubitemid 27152545)